NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
Sun Yat-sen University
UNICANCER
Criterium, Inc.
Grupo Espanol Multidisciplinario del Cancer Digestivo
Sanofi
European Organisation for Research and Treatment of Cancer - EORTC